Patisiran: connect RNA interference to a neuropathy endpoint

Clarus Biotech Review

APOLLO joined a molecular mechanism to 18-month clinical measures in a defined hereditary disease.

Patisiran provides a specific example of an RNA mechanism reaching a patient-relevant trial question. APOLLO randomized 225 patients with hereditary transthyretin amyloidosis and polyneuropathy: 148 to patisiran and 77 to placebo. The main neurological measurement was mNIS+7, assessed over 18 months. [1]

## The bridge beyond target engagement

At month 18, the least-squares mean change in mNIS+7 was −6.0 with patisiran and +28.0 with placebo, a between-group difference of −34.0 points. Lower scores represented less neuropathy impairment on this scale. The study also reported a −21.1-point between-group difference in the Norfolk quality-of-life measure. These are outcome-specific effects, not percentages of disease eradication. [1]

## Mechanism and clinical relevance need distinct evidence

RNA interference supplies the biological rationale for reducing transthyretin production. It does not make a functional result redundant. A development team needs exposure and pharmacodynamic evidence, but it also needs a population, comparator, and measurement that can establish whether biological activity matters clinically. FDA's original 2018 label identified the approved adult polyneuropathy use and the infusion-related safety and administration requirements. [2]

## An operational milestone contains the measurement burden

An 18-month neurological outcome creates retention, assessor-consistency, missing-data, and treatment-delivery dependencies. Those belong in the milestone charter. A short-term biomarker result can be decision-relevant while remaining insufficient to answer the later functional question. The timing of each evidence layer should be explicit in financing and study plans.

## A program-specific inflection thesis

For an RNA program, state which biological uncertainty a target-engagement study retires and which clinical uncertainty the later trial addresses. APOLLO illustrates a successful connection in a particular disease; it does not validate every RNA target or delivery platform. The relevant operating plan funds the bridge between the two claims and measures whether that bridge remains interpretable.

Source adaptation: the Serna Bio transcriptome working paper supplied the claim-to-evidence lens. This revision applies that lens to the public APOLLO record rather than repeating the platform-portfolio article.

Sources

https://pubmed.ncbi.nlm.nih.gov/29972753/

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf

Original article: https://www.clarusreview.bio/articles/rna-therapeutics-proof-of-mechanism